In Brief This Week: Luminex; Life Technologies; CombiMatrix; Danaher; Biotrial, Warnex; Almac | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex's board of directors has authorized the firm to repurchase up to the lesser of $22.5 million worth or 900,000 shares of the company's outstanding common stock. The repurchase program is scheduled to expire Dec. 31, 2013, Luminex noted in a regulatory filing with the US Securities and Exchange Commission. As of Feb. 21, Luminex had nearly 41.7 million common shares outstanding, according to its Form 10-K filed on Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.